Michael Powell Net Worth

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Michael Powell GRTX stock SEC Form 4 insiders trading

Michael has made over 3 trades of the Galera Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 6,512 units of GRTX stock worth $14,912 on 12 September 2016.

The largest trade he's ever made was buying 857,142 units of Galera Therapeutics Inc stock on 5 October 2015 worth over $5,999,994. On average, Michael trades about 18,242 units every 7 days since 2003. As of 12 September 2016 he still owns at least 9,540 units of Galera Therapeutics Inc stock.

You can see the complete history of Michael Powell stock trades at the bottom of the page.

Michael Powell biography

Dr. Michael F. Powell Ph.D. serves as Independent Chairman of the Board of the Company. He has served as a member of our Board of Directors since November 2016 and as its Chair since July 2017. Dr. Powell is a General Partner at Sofinnova Investments, a biopharmaceutical investment firm, where he has worked in his current role since joining the firm in 1997. Dr. Powell previously was Group Leader of Drug Delivery at Genentech from 1990 until 1997, and Director of Product Development at Cytel from 1987 until 1990. Dr. Powell currently serves as the Chair of Checkmate Pharma and Dauntless Pharmaceuticals and sits on the board of Pionyr Immunotherapeutics and Synlogic. He also serves on the Washington University Board of Trustees in St. Louis and is an Adjunct Professor of Pharmaceutical Chemistry at the University of Kansas. Dr. Powell holds a Ph.D. in Physical Chemistry from the University of Toronto and he completed post-doctoral studies in Bioorganic Chemistry at the University of California as a National Science and Engineering Research Council Scholar. Powell is qualified to serve on our Board of Directors due to his extensive experience in drug development and investing in biopharmaceutical companies.

What is the salary of Michael Powell?

As the Independent Chairman of the Board of Galera Therapeutics Inc, the total compensation of Michael Powell at Galera Therapeutics Inc is $184,323. There are 9 executives at Galera Therapeutics Inc getting paid more, with J. Mel Sorensen having the highest compensation of $2,465,100.

How old is Michael Powell?

Michael Powell is 65, he's been the Independent Chairman of the Board of Galera Therapeutics Inc since 2017. There are 3 older and 14 younger executives at Galera Therapeutics Inc. The oldest executive at Galera Therapeutics Inc is Joel F. Sussman, 72, who is the Chief Accounting Officer & Treasurer.

What's Michael Powell's mailing address?

Michael's mailing address filed with the SEC is C/O GALERA THERAPEUTICS, INC., 45 LIBERTY BLVD #230, MALVERN, PA, 19355.

Insiders trading at Galera Therapeutics Inc

Over the last 5 years, insiders at Galera Therapeutics Inc have traded over $19,201,067 worth of Galera Therapeutics Inc stock and bought 3,540,438 units worth $29,883,202 . The most active insiders traders include Holdings A/S Novo, Group Inc Blackstone Group ... e Bioventures Ltd Novartis Ag.... On average, Galera Therapeutics Inc executives and independent directors trade stock every 47 days with the average trade being worth of $11,809. The most recent stock trade was executed by Mel Sorensen on 16 August 2024, trading 67,015 units of GRTX stock currently worth $4,691.

What does Galera Therapeutics Inc do?

galera therapeutics, inc. is a pharmaceuticals company located in 101 lindenwood dr, malvern, pennsylvania, united states.

Galera Therapeutics Inc executives and stock owners

Galera Therapeutics Inc executives and other stock owners filed with the SEC include:

• J. Mel Sorensen,
  President, Chief Executive Officer, Director
• Christopher Degnan,
  Chief Financial Officer
• Robert Beardsley,
  Chief Operating Officer
• Dr. J. Mel Sorensen,
  CEO, Pres & Director
• Christopher Degnan,
  CFO & Sec.
• Dr. Robert A. Beardsley,
  Co-Founder & COO
• Arthur Fratamico,
  Chief Business Officer
• Jon Holmlund,
  Chief Medical Officer
• Lawrence Alleva,
  Independent Director
• Michael Powell,
  Independent Chairman of the Board
• Emmett Cunningham,
  Director
• Kevin Lokay,
  Independent Director
• Linda West,
  Independent Director
• Joel Sussman,
  Chief Accounting Officer
• Mark J. Bachleda M.B.A., Pharm.D.,
  Chief Commercial Officer
• Arthur J. Fratamico,
  Chief Bus. Officer
• Dr. Jon T. Holmlund,
  Chief Medical Officer
• Jennifer Evans Stacey Esq.,
  Chief Legal & Compliance Officer and Sec.
• Dr. Dennis P. Riley Ph.D.,
  Chief Scientific Officer
• Joel F. Sussman,
  Chief Accounting Officer & Treasurer
• Bioventures Ltd Novartis Ag...,
  
• Chris Degnan,
  Chief Financial Officer
• Jason Fuller,
  Director
• Iv A, L.P.Clarus Iv B, L.P....,
  
• Group Inc Blackstone Group ...,
  
• Clarus Gp L.P.Blackstone Cl...,
  
• Enterprise Associates 14, L...,
  
• Venture Partners Ix, L.P.So...,
  
• Dennis Riley,
  Chief Scientific Officer
• Holdings A/S Novo,
  10% owner
• Mark Bachleda,
  Chief Commercial Officer
• Jennifer Evans Stacey,
  See Remarks
• Yair Schneid,
  10% owner
• Eugene P. Kennedy,
  Chief Medical Officer
• Mel Sorensen,
  President and CEO